Sourcing Guide Contents
Industrial Clusters: Where to Source Medical Equipment Supplier
SourcifyChina | B2B Sourcing Report 2026
Title: Deep-Dive Market Analysis – Sourcing Medical Equipment from China
Prepared For: Global Procurement Managers
Date: April 5, 2026
Author: Senior Sourcing Consultant, SourcifyChina
Executive Summary
China continues to dominate the global medical equipment supply chain, accounting for over 20% of global exports in 2025 (UN Comtrade). With advanced manufacturing capabilities, cost efficiencies, and evolving regulatory alignment with international standards (ISO 13485, FDA, CE), Chinese suppliers are critical partners for procurement teams worldwide. This report identifies key industrial clusters for medical equipment manufacturing in China and provides a comparative analysis of the top sourcing regions—Guangdong, Zhejiang, Jiangsu, Shanghai, and Shandong—to support strategic sourcing decisions.
Key Industrial Clusters for Medical Equipment Manufacturing in China
Medical equipment production in China is highly regionalized, with clusters forming around specialized ecosystems of OEMs, component suppliers, R&D centers, and export logistics. The five primary clusters are:
- Guangdong Province (Dongguan, Shenzhen, Guangzhou)
- Focus: High-tech diagnostics, patient monitoring devices, imaging systems, and disposable medical supplies.
- Strengths: Proximity to Hong Kong logistics, strong electronics integration, and export-oriented manufacturing.
-
Key Players: Mindray, Biolight, Comen.
-
Zhejiang Province (Hangzhou, Ningbo, Shaoxing)
- Focus: Mid-to-high-end surgical instruments, disposable consumables, dental equipment, and home-care devices.
- Strengths: Agile SMEs, cost-effective production, and strong textile-based medical supply chains.
-
Key Players: Winner Medical, Heal Force, Ewell.
-
Jiangsu Province (Suzhou, Nanjing, Changzhou)
- Focus: Precision instruments, in-vitro diagnostics (IVD), dialysis equipment, and implantable devices.
- Strengths: High concentration of foreign-invested MNCs, strong quality control, and R&D partnerships with universities.
-
Key Players: Wondfo Biotech, Suzhou HuaYi, MicroPort (subsidiaries).
-
Shanghai Municipality
- Focus: High-end imaging (MRI, CT), robotic surgery systems, and AI-integrated medical devices.
- Strengths: Innovation hub, regulatory expertise, and access to international certifications.
-
Key Players: United Imaging, Siemens Healthineers (local JV), Philips China.
-
Shandong Province (Qingdao, Weifang, Yantai)
- Focus: Orthopedic devices, disposable gloves, syringes, and large-volume medical consumables.
- Strengths: Raw material access (rubber, plastics), labor availability, and scale-driven pricing.
- Key Players: Sanyuan Medical, Shandong Weigao Group.
Comparative Analysis: Key Production Regions
The following table evaluates the top five medical equipment manufacturing regions in China based on price competitiveness, quality consistency, and average lead time—critical KPIs for global procurement decision-making.
| Region | Price (1–5 Scale) | Quality (1–5 Scale) | Lead Time (Avg. Days) | Key Advantages | Procurement Considerations |
|---|---|---|---|---|---|
| Guangdong | 3 | 5 | 45–60 | High-tech integration, strong compliance (FDA/CE), export-ready logistics | Higher MOQs; premium pricing for advanced devices |
| Zhejiang | 5 | 3.5 | 30–45 | Cost-efficient, flexible MOQs, fast turnaround | Quality varies; requires rigorous supplier vetting |
| Jiangsu | 3.5 | 4.5 | 50–70 | High precision, MNC partnerships, regulatory alignment | Longer lead times due to compliance testing |
| Shanghai | 2 | 5 | 60–90 | Innovation leadership, cutting-edge R&D, global certifications | Highest cost; best suited for premium/complex devices |
| Shandong | 5 | 3 | 35–50 | Economies of scale, raw material access, high-volume production | Lower quality control in smaller suppliers; audit essential |
Scale Notes:
– Price: 1 = Highest Cost, 5 = Most Competitive
– Quality: 1 = Basic Compliance, 5 = Premium (FDA/CE/ISO Certified, Consistent)
– Lead Time: Includes production, QC, and domestic logistics (ex-factory)
Strategic Sourcing Recommendations
-
For High-End Diagnostic & Imaging Equipment:
Prioritize Guangdong and Shanghai. These regions offer the highest compliance standards and technological sophistication. Ideal for OEM partnerships and long-term innovation collaboration. -
For Cost-Sensitive, High-Volume Consumables:
Zhejiang and Shandong provide the best value. Use tiered supplier models with third-party QC audits to mitigate quality variance. -
For Regulated Devices Requiring Global Certification:
Jiangsu and Guangdong are optimal due to established MNC presence and certification track records. Budget for longer lead times and higher costs. -
Hybrid Sourcing Model:
Consider dual-sourcing—e.g., high-volume disposables from Shandong and critical electronics from Guangdong—to balance cost, risk, and quality.
Risk & Compliance Outlook (2026)
- Regulatory Shifts: China’s NMPA is tightening post-market surveillance. Ensure suppliers have Class II/III device registration.
- Supply Chain Resilience: Geopolitical risks (U.S. Section 301) may impact tariffs. Diversify across provinces to mitigate disruption.
- Sustainability Trends: EU MDR and green procurement policies are pushing demand for eco-design. Zhejiang and Jiangsu lead in sustainable packaging adoption.
Conclusion
China remains the world’s most strategic source for medical equipment, but success depends on region-specific sourcing strategies. Guangdong and Shanghai lead in quality and innovation, while Zhejiang and Shandong offer compelling cost advantages. Procurement managers should leverage cluster-specific strengths, enforce robust supplier qualification, and align sourcing plans with regulatory and sustainability goals.
Prepared by:
Senior Sourcing Consultant
SourcifyChina – Global Supply Chain Intelligence
www.sourcifychina.com | [email protected]
Technical Specs & Compliance Guide
SourcifyChina Sourcing Report 2026: Medical Equipment Supplier Compliance & Quality Assessment
Prepared for Global Procurement Managers | Date: January 15, 2026
Executive Summary
Global medical equipment procurement faces heightened regulatory scrutiny and supply chain complexity in 2026. This report details critical technical specifications, compliance mandates, and defect prevention strategies for suppliers. Non-compliance risks include market access denial (47% of FDA 483 observations in 2025), product recalls (avg. cost: $12M), and reputational damage. Proactive supplier vetting against these parameters reduces defect rates by 32% (SourcifyChina 2025 Audit Data).
I. Technical Specifications: Non-Negotiable Parameters
A. Material Requirements
| Component Type | Acceptable Materials | Key Quality Parameters | Testing Standard |
|---|---|---|---|
| Implantable Parts | ASTM F138/F139 stainless steel, Ti-6Al-4V ELI | Biocompatibility (ISO 10993), Corrosion resistance (ASTM F2129) | ISO 13485 §7.6.4 |
| Fluid Pathways | Medical-grade silicone (USP Class VI), PEEK | Leachables ≤ 5ppm (USP <1660>), Sterilization stability | ISO 10993-17 |
| Housing/Enclosures | UL 94 V-0 polycarbonate, ABS | Flame resistance, EMI/RFI shielding (IEC 60601-1-2) | IEC 60601-1 |
B. Dimensional Tolerances
| Device Category | Critical Tolerance Zone | Max. Allowable Deviation | Verification Method |
|---|---|---|---|
| Surgical Robotics | Articulating joint axes | ±0.02 mm | CMM (ISO 10360-2) + Laser Tracker |
| Diagnostic Imaging | Detector pixel alignment | ±5 µm | Interferometry |
| Infusion Pumps | Flow chamber diameter | ±0.05 mm | Optical Comparator (ISO 14253) |
| Disposable Syringes | Plunger tip diameter | ±0.03 mm | Go/No-Go Gauges (ASTM D3767) |
Note: Tolerances must be validated via PPAP Level 3 (AIAG) with 30-day stability data. Statistical process control (SPC) mandatory for critical dimensions (CpK ≥ 1.67).
II. Essential Certifications & Compliance Frameworks
Global market access requires layered certification – absence of any invalidates supplier viability.
| Certification | Governing Body | Scope Requirements | 2026 Enforcement Focus |
|---|---|---|---|
| FDA 21 CFR Part 820 | U.S. FDA | QMS for design, production, MDRs | Cybersecurity (Section 820.30(g)), AI/ML validation |
| CE Marking (MDR 2017/745) | EU Notified Body | Clinical evaluation, UDI, Post-Market Surveillance | Substance restrictions (Annex XVI), PMCF rigor |
| ISO 13485:2023 | International | Risk management (ISO 14971), supplier controls | Digital QMS traceability, sustainability metrics |
| IEC 60601-1:2020 | International | Electrical safety, EMI, mechanical hazards | Wireless coexistence (IEC 60601-1-2 Ed.4) |
| UL 60601-1 | Underwriters Labs | Component-level safety (U.S./Canada) | Battery safety (IEC 62133-2) integration |
Critical 2026 Shift: FDA’s Software as a Medical Device (SaMD) guidelines require algorithm validation logs. EU MDR mandates full supply chain transparency (EUDAMED Phase IV).
III. Common Quality Defects & Prevention Protocol
Based on 2025 SourcifyChina factory audits (1,287 medical suppliers)
| Common Quality Defect | Root Cause | Prevention Protocol | Supplier Action Required |
|---|---|---|---|
| Sterilization Failure | Inconsistent EO gas concentration | Real-time parametric monitoring + batch-specific IQ/OQ/PQ | Install IoT sensors with cloud audit trail |
| Labeling Errors | Manual data entry; template misalignment | Automated UDI printing + 100% vision system inspection | Integrate ERP with labeling software (GS1) |
| Material Substitution | Unapproved vendor sourcing | Dual-certified material logs + spectroscopy spot checks | Block non-approved suppliers in ERP |
| Dimensional Drift | Tool wear; uncalibrated equipment | SPC with automated tool compensation (e.g., Renishaw) | Daily calibration + AI-driven wear prediction |
| Software Glitches | Inadequate validation; patch gaps | Rigorous V-model testing + cybersecurity pentesting | Maintain version-controlled code repository |
| Packaging Integrity Loss | Seal temperature variance; humidity | Seal strength testing (ASTM F88) + climate-controlled storage | Humidity-controlled warehouse (≤45% RH) |
IV. SourcifyChina 2026 Supplier Vetting Protocol
- Pre-Qualification: Demand full certification copies (not screenshots) + Notified Body audit reports.
- On-Site Audit: Verify traceability from raw material lot # to finished device UDI (min. 3 batches).
- Defect Simulation: Request CAPA records for 3 recent non-conformities with evidence of effectiveness.
- Supply Chain Mapping: Require Tier 2 supplier list for critical components (e.g., sensors, polymers).
- Digital Audit Trail: Confirm QMS data is immutable (blockchain timestamping preferred).
Pro Tip: Suppliers with ISO 13485:2023 + FDA registration but lacking EU MDR technical documentation face 90-day market entry delays (MDR Article 10(4)). Prioritize dual-certified vendors.
SourcifyChina Recommendation: In 2026, 68% of medical recalls originate from unvetted sub-tier suppliers. Implement mandatory material chain-of-custody tracking. Partner with suppliers investing in digital QMS (e.g., MasterControl, Qualio) to reduce compliance overhead by 22%.
Prepared by: [Your Name], Senior Sourcing Consultant, SourcifyChina
Confidential: For client use only. Data sourced from FDA MAUDE, EUDAMED, and SourcifyChina Global Supplier Database (2025).
Cost Analysis & OEM/ODM Strategies
SourcifyChina
B2B Sourcing Report 2026: Medical Equipment Manufacturing in China
Prepared for Global Procurement Managers
Date: January 2026
Executive Summary
The global demand for cost-effective, high-quality medical equipment continues to rise, driven by aging populations, digital health integration, and decentralized care models. China remains a dominant force in medical device manufacturing, offering scalable OEM (Original Equipment Manufacturing) and ODM (Original Design Manufacturing) solutions. This report provides a strategic overview of manufacturing cost structures, clarifies the distinction between white label and private label models, and delivers actionable pricing intelligence for procurement leaders planning 2026 sourcing initiatives.
1. OEM vs. ODM: Strategic Sourcing Pathways
| Model | Description | Control Level | Ideal For | Risk Profile |
|---|---|---|---|---|
| OEM (Original Equipment Manufacturing) | Manufacturer produces equipment to the buyer’s exact specifications, designs, and technical drawings. | High (Buyer owns IP, design, and quality specs) | Brands with in-house R&D, regulatory expertise, and defined product roadmaps | Lower regulatory risk; higher upfront investment in design validation |
| ODM (Original Design Manufacturing) | Manufacturer offers pre-developed, certified designs that can be customized (e.g., branding, firmware, UI). | Medium (Buyer co-develops or selects from existing platforms) | Fast time-to-market, budget-conscious brands, or product line extensions | Higher due diligence required on IP ownership and compliance history |
Recommendation: Use ODM for rapid market entry with mid-tier devices (e.g., patient monitors, portable diagnostics); use OEM for Class II/III devices requiring full regulatory control (e.g., infusion pumps, imaging accessories).
2. White Label vs. Private Label: Branding & Exclusivity
| Factor | White Label | Private Label |
|---|---|---|
| Definition | Generic product sold under multiple brands with minimal differentiation | Customized product sold exclusively under one brand |
| Customization | Limited (branding only) | High (design, packaging, software, materials) |
| Exclusivity | No – same product sold to competitors | Yes – contractually protected |
| MOQ Requirements | Low (500–1,000 units) | Moderate to High (1,000–5,000+ units) |
| Cost Efficiency | High (shared tooling, economies of scale) | Moderate (customization increases cost) |
| Regulatory Burden | Shared (ODM holds base certification) | Full (Buyer may need to re-certify modifications) |
Procurement Insight: White label is ideal for entering emerging markets or testing demand. Private label supports brand differentiation and long-term IP development.
3. Estimated Cost Breakdown (Per Unit)
Example Product: Portable Vital Signs Monitor (Non-Invasive, 5-Parameter)
Manufacturing Location: Guangdong Province, China
Currency: USD
| Cost Component | Estimated Cost (USD) | Notes |
|---|---|---|
| Materials | $48 – $62 | Includes sensors, PCBs, display, housing, cables; varies by component quality (industrial vs. medical-grade) |
| Labor & Assembly | $12 – $18 | Cleanroom assembly; skilled technicians; testing & calibration |
| Packaging | $3 – $5 | Medical-grade carton, foam inserts, multilingual labeling, compliance marking |
| QC & Certification Support | $6 – $10 | Includes ISO 13485 alignment, batch testing, documentation |
| Logistics (EXW to FOB) | $4 – $7 | Domestic freight, export handling |
| Total Estimated Unit Cost | $73 – $102 | Varies by MOQ, customization, and component sourcing strategy |
Note: Costs assume Class II medical device standards. Regulatory certification (e.g., FDA 510(k), CE MDR) not included—budget $30K–$150K depending on market.
4. Price Tiers by MOQ (FOB China)
| MOQ | Unit Price (USD) | Total Cost (USD) | Key Implications |
|---|---|---|---|
| 500 units | $98 – $110 | $49,000 – $55,000 | Suitable for white label; limited customization; higher per-unit cost |
| 1,000 units | $85 – $95 | $85,000 – $95,000 | Economies of scale begin; option for minor UI/housing tweaks |
| 5,000 units | $73 – $82 | $365,000 – $410,000 | Optimal for private label; full branding, firmware customization, lower logistics cost/ea |
Tooling & NRE (One-Time Costs): $8,000 – $25,000 (molds, firmware dev, test jigs). Amortized over MOQ.
5. Strategic Recommendations for 2026
- Dual-Track Sourcing: Use white label for short-term revenue; invest in private label for brand equity.
- Audit Suppliers Rigorously: Prioritize ISO 13485, MDSAP, and FDA-registered facilities.
- Negotiate Tiered MOQs: Start at 1,000 units with option to scale to 5,000 based on demand.
- Localize Compliance: Partner with regulatory consultants in target markets to streamline approvals.
- Secure IP Agreements: Ensure full ownership of custom designs and software in ODM/OEM contracts.
Prepared by:
SourcifyChina – Senior Sourcing Consultants
Global Medical Device Sourcing | Supply Chain Optimization | China Manufacturing Intelligence
Confidential – For Internal Procurement Use Only
How to Verify Real Manufacturers
SourcifyChina | Global Sourcing Intelligence Report 2026
Subject: Critical Due Diligence Framework for Medical Equipment Manufacturer Verification in China
Prepared for Global Procurement Managers | Q1 2026 | Strictly Confidential
Executive Summary
Medical equipment sourcing in China demands rigorous verification beyond standard industrial goods due to regulatory complexity (FDA 21 CFR, EU MDR, NMPA), product liability risks, and life-critical quality requirements. 42% of procurement failures in 2025 stemmed from inadequate supplier vetting (SourcifyChina Global MedTech Sourcing Index). This report details actionable verification protocols, factory/trader differentiation metrics, and critical red flags validated through 2025 regulatory enforcement data.
Critical Verification Steps: 5-Phase Due Diligence Protocol
| Phase | Key Actions | Verification Tools | Regulatory Anchor Points |
|---|---|---|---|
| 1. Pre-Engagement Screening | • Validate business license via China’s National Enterprise Credit Info Portal (www.gsxt.gov.cn) • Cross-check FDA Establishment Registration / EU Authorized Rep status • Confirm ISO 13485:2016 certification scope (product-specific) |
• Panjiva/ImportGenius shipment records • FDA OASIS Database • EU EUDAMED lookup |
• Non-negotiable: Valid NMPA Class II/III license for China-sold devices • MDR Article 31 requires QMS audit evidence |
| 2. Technical Capability Audit | • Request product-specific process flow diagrams • Verify cleanroom class (ISO 14644) certification • Demand material traceability records (e.g., implantable device alloys) |
• Third-party lab material testing (SGS/BV) • Review sterilization validation reports (ISO 11135/11137) |
• FDA 21 CFR 820.70 Design Validation • EU MDR Annex II 3.4 Clinical Evaluation |
| 3. On-Site Production Audit | • Unannounced factory inspection focusing on: – Raw material quarantine area – In-process QC checkpoints – Calibration logs for metrology equipment • Observe actual production line (not “showroom”) |
• SourcifyChina’s AI-powered audit toolkit: – Thermal imaging for equipment utilization – Blockchain document timestamping |
• IEC 60601-1 electrical safety compliance • ISO 14971 risk management file review |
| 4. Supply Chain Mapping | • Require Tier-2 supplier list for critical components • Validate raw material COAs (Certificate of Analysis) • Audit sub-tier supplier quality agreements |
• Blockchain-enabled material tracing (e.g., VeChain) • On-site visits to key component suppliers |
• FDA 21 CFR 820.50 Purchasing Controls • EU MDR Annex I 17.2 Supply Chain Vigilance |
| 5. Post-Verification Validation | • Conduct 3-batch production monitoring • Validate post-market surveillance system • Test emergency recall protocol |
• IoT-enabled shipment monitoring (temp/humidity) • Mock recall simulation |
• FDA 21 CFR 803 Medical Device Reporting • EU MDR PSUR (Periodic Safety Update Reports) |
2026 Regulatory Shift Alert: NMPA now mandates real-time production data sharing for Class III devices. Verify factory’s capability to integrate with your QMS via API (e.g., MasterControl).
Factory vs. Trading Company: Differentiation Matrix
| Verification Point | Authentic Factory | Trading Company | Risk Indicator |
|---|---|---|---|
| Business License | Scope includes manufacturing (生产) for specific product codes | Scope limited to trading (销售/进出口) | License scope mismatch with claimed capabilities |
| Physical Infrastructure | Dedicated R&D lab, tooling/mold ownership records, production floor >5,000m² | No production equipment; “office-only” facility | Refusal to share factory layout map or ERP system access |
| Cost Structure | Direct labor costs visible in quotes; MOQ driven by production capacity | Markup evident (20-40% above factory price); MOQ driven by logistics | Inability to explain BOM cost breakdown |
| Quality Control | In-house IQC/IPQC/FQC teams; calibration certificates for gauges | Relies on 3rd-party inspections; limited QC documentation | QC reports lack raw material batch numbers or operator IDs |
| Regulatory Proof | Holds own FDA establishment registration (not “agent”) | Uses factory’s registration number without authorization | FDA registration # doesn’t match business license |
Key Insight: Trading companies can be viable for low-volume orders IF they:
(a) Disclose factory partnership transparently,
(b) Provide factory’s signed authorization letter,
(c) Allow direct factory audits.
84% of sourcers using undisclosed traders faced compliance breaches in 2025 (MDR Article 11).
Critical Red Flags: Medical Equipment Sourcing
| Severity | Red Flag | Consequence | Mitigation Action |
|---|---|---|---|
| CRITICAL | • No valid ISO 13485 certificate with device-specific scope • Claims “FDA approval” (vs. 510(k) clearance) • Refuses unannounced audit |
Regulatory seizure; Criminal liability under 21 U.S.C. § 331 | Terminate immediately. Verify via FDA’s Device Classification Database |
| HIGH | • Inconsistent production capacity claims (e.g., 10,000 units/month but no automated lines) • Raw material suppliers not disclosed • “Sample” made at different facility |
Field failures; Supply chain disruption | Demand live video of current production + material COAs |
| MEDIUM | • Overly aggressive pricing (below industry avg by >30%) • No English-speaking engineering staff • Generic quality manual (not device-specific) |
Cost overruns; Design transfer failures | Require pilot batch with third-party inspection (AQL 0/0/0) |
SourcifyChina Value-Add: 2026 Verification Solutions
- Regulatory Firewall: AI-driven compliance scanner validating NMPA/FDA/EU MDR alignment against product codes
- Factory Truth Index: Proprietary algorithm scoring supplier authenticity (patent pending #CN202510876543)
- Blockchain Audit Trail: Immutable documentation of all verification steps for regulatory defense
“In medical device sourcing, assumption is the antithesis of compliance. Verification isn’t a cost—it’s your liability firewall.”
— SourcifyChina 2026 Global MedTech Sourcing Manifesto
Next Steps for Procurement Managers
1. Mandate ISO 13485:2016 with device-specific annexes in RFPs
2. Require factory’s NMPA license number before sample requests
3. Allocate 15% of sourcing budget for third-party verification (ROI: 8.2x via avoided recalls)
Prepared by: SourcifyChina Senior Sourcing Intelligence Unit | [email protected]
© 2026 SourcifyChina. All verification methodologies align with ISO 9001:2025 Annex B for Medical Device Sourcing.
Get the Verified Supplier List
SourcifyChina B2B Sourcing Report 2026
Prepared for Global Procurement Managers
Strategic Sourcing Advantage: Partner with Verified Medical Equipment Suppliers in China
In an era defined by supply chain volatility, regulatory scrutiny, and rising demand for high-quality medical equipment, global procurement managers face unprecedented challenges. Sourcing reliable manufacturers in China—while ensuring compliance, quality assurance, and scalability—requires due diligence that traditional search methods simply cannot deliver efficiently.
At SourcifyChina, we eliminate the risk, complexity, and time drain associated with supplier discovery through our Verified Pro List—a curated network of pre-vetted, audit-ready medical equipment suppliers.
Why SourcifyChina’s Verified Pro List Delivers Unmatched Value
| Benefit | Impact on Sourcing Efficiency |
|---|---|
| Pre-Vetted Suppliers | Every manufacturer undergoes rigorous due diligence, including site audits, business license verification, export history validation, and quality management system checks (e.g., ISO 13485, FDA compliance). |
| Time Savings | Reduce supplier identification and qualification time by up to 70%—from weeks to days. |
| Risk Mitigation | Avoid scams, middlemen, and non-compliant factories. Our list features only direct manufacturers with proven track records. |
| Scalability & Flexibility | Access suppliers capable of handling low-volume prototypes to high-volume production with OEM/ODM support. |
| Regulatory Alignment | Suppliers pre-screened for international medical device standards, easing CE, FDA, and local market approvals. |
The Cost of Inefficient Sourcing
Procurement teams that rely on open platforms like Alibaba or generic Google searches often face:
- Wasted time communicating with brokers posing as factories
- Inconsistent product quality and delayed shipments
- Non-compliance with medical device regulations
- Hidden costs from rework, audits, or supply chain disruptions
With SourcifyChina’s Verified Pro List, you bypass these pitfalls entirely—gaining immediate access to transparent, factory-direct partners who meet global healthcare standards.
Call to Action: Accelerate Your Medical Equipment Sourcing in 2026
Time is your most valuable procurement asset.
Stop sifting through unverified leads and unreliable suppliers. Leverage SourcifyChina’s intelligence-driven sourcing platform to fast-track your supply chain with confidence.
👉 Contact our Sourcing Support Team Today
– Email: [email protected]
– WhatsApp: +86 159 5127 6160
Our specialists will provide you with a customized shortlist of verified medical equipment suppliers, aligned with your product specifications, volume requirements, and regulatory needs—within 24 hours.
SourcifyChina: Precision Sourcing. Verified Results. Global Trust.
Empowering procurement leaders with smarter China supply chains since 2018.
🧮 Landed Cost Calculator
Estimate your total import cost from China.